CStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%

Reuters03-26 17:01

<a href="https://laohu8.com/S/02616">CStone Pharmaceuticals</a> reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%

CStone reported new development progress for CS2009, positioning the program as a potential differentiated entrant in immuno-oncology by combining multiple established targets into a single drug candidate.
The company said it plans to start its first global Phase 3 multi-regional clinical trials by the end of 2026, initially targeting non-small cell lung cancer, colorectal cancer, and small cell lung cancer.
CStone disclosed that 113 patients had been enrolled in the Phase 1 study as of mid-March 2026, supporting continued advancement of the asset into later-stage development.
The company also said additional Phase 1 and Phase 2 data are expected to be presented in 2026 at major oncology conferences, which could influence partnering and competitive positioning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068889), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622278830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622278830","market":"nz","top_or_hot":-1,"title":"CStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/02616\">CStone Pharmaceuticals</a> reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          CStone reported new development progress for CS2009, positioning the program as a potential differentiated entrant in immuno-oncology by combining multiple established targets into a single drug candidate.\n        </li>\n<li>\n          The company said it plans to start its first global Phase 3 multi-regional clinical trials by the end of 2026, initially targeting non-small cell lung cancer, colorectal cancer, and small cell lung cancer.\n        </li>\n<li>\n          CStone disclosed that 113 patients had been enrolled in the Phase 1 study as of mid-March 2026, supporting continued advancement of the asset into later-stage development.\n        </li>\n<li>\n          The company also said additional Phase 1 and Phase 2 data are expected to be presented in 2026 at major oncology conferences, which could influence partnering and competitive positioning.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068889), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/02616\">CStone Pharmaceuticals</a> reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          CStone reported new development progress for CS2009, positioning the program as a potential differentiated entrant in immuno-oncology by combining multiple established targets into a single drug candidate.\n        </li>\n<li>\n          The company said it plans to start its first global Phase 3 multi-regional clinical trials by the end of 2026, initially targeting non-small cell lung cancer, colorectal cancer, and small cell lung cancer.\n        </li>\n<li>\n          CStone disclosed that 113 patients had been enrolled in the Phase 1 study as of mid-March 2026, supporting continued advancement of the asset into later-stage development.\n        </li>\n<li>\n          The company also said additional Phase 1 and Phase 2 data are expected to be presented in 2026 at major oncology conferences, which could influence partnering and competitive positioning.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068889), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL72mNTQ:1","article_id":"2622278830","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622278830","pubTimestamp":1774515681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CStone reported new development progress for CS2009, positioning the program as a potential differentiated entrant in immuno-oncology by combining multiple established targets into a single drug candidate.The company said it plans to start its first global Phase 3 multi-regional clinical trials by the end of 2026, initially targeting non-small cell lung cancer, colorectal cancer, and small cell lung cancer.CStone disclosed that 113 patients had been enrolled in the Phase 1 study as of mid-March 2026, supporting continued advancement of the asset into later-stage development.The company also said additional Phase 1 and Phase 2 data are expected to be presented in 2026 at major oncology conferences, which could influence partnering and competitive positioning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02616":"基石药业-B"},"translate_title":"基石药业报告CS2009 I/II期进展；PD-L1 TPS≥50%的一线非小细胞肺癌ORR升至90%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":0.9},"content_text":"CStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%\n    \n\n\n          CStone reported new development progress for CS2009, positioning the program as a potential differentiated entrant in immuno-oncology by combining multiple established targets into a single drug candidate.\n        \n\n          The company said it plans to start its first global Phase 3 multi-regional clinical trials by the end of 2026, initially targeting non-small cell lung cancer, colorectal cancer, and small cell lung cancer.\n        \n\n          CStone disclosed that 113 patients had been enrolled in the Phase 1 study as of mid-March 2026, supporting continued advancement of the asset into later-stage development.\n        \n\n          The company also said additional Phase 1 and Phase 2 data are expected to be presented in 2026 at major oncology conferences, which could influence partnering and competitive positioning.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068889), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622278830","isCrawlerRequest":true}